Liraglutide vs Lactoferricin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Liraglutide
Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.
Full details →Lactoferricin
Lactoferricin is an antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. It has potent antibacterial, antiviral, and antifungal properties.
Full details →Side-by-Side Comparison
| Aspect | Liraglutide | Lactoferricin |
|---|---|---|
| Mechanism | Binds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects. | Binds to and disrupts microbial membranes through electrostatic interactions. Also binds to lipopolysaccharide (LPS) to neutralize endotoxins and has immunomodulatory effects. |
| Typical Dosage | Saxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily. | Research applications vary widely. Oral lactoferrin supplements (containing lactoferricin precursor) typically dosed at 100-400mg daily. |
| Administration | Subcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications. | Available through lactoferrin supplementation orally. Purified lactoferricin primarily used in research settings. |
| Side Effects | Nausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use. | Lactoferrin supplementation is generally well-tolerated. May cause GI upset in some individuals. Derived from milk so caution with dairy allergies. |
| Best For |